SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria
Helena Barrasa, Jordi Rello, Sofia Tejada, Alejandro Martín, Goiatz Balziskueta, Cristina Vinuesa, Borja Fernández-Miret, Ana Villagra, Ana Vallejo, Ana San Sebastián, Sara Cabañes, Sebastián Iribarren, Fernando Fonseca, Javier Maynar, Alava COVID-19 Study Investigators, Helena Barrasa, Jordi Rello, Sofia Tejada, Alejandro Martín, Goiatz Balziskueta, Cristina Vinuesa, Borja Fernández-Miret, Ana Villagra, Ana Vallejo, Ana San Sebastián, Sara Cabañes, Sebastián Iribarren, Fernando Fonseca, Javier Maynar, Alava COVID-19 Study Investigators
Abstract
Purpose: Community transmission of SARS-CoV-2 was detected in Spain in February 2020, with 216% intensive care unit (ICU) capacity expanded in Vitoria by March 18th, 2020.
Methods: We identified patients from the two public hospitals in Vitoria who were admitted to ICU with confirmed infection by SARS-CoV-2. Data reported here were available in April 6th, 2020. Mortality was assessed in those who completed 15-days of ICU stay.
Results: We identified 48 patients (27 males) with confirmed SARS-CoV-2. Median [interquartile range (IQR)] age of patients was 63 [51-75] years. Symptoms began a median of 7 [5-12] days before ICU admission. The most common comorbidities identified were obesity (48%), arterial hypertension (44%) and chronic lung disease (37%). All patients were admitted by hypoxemic respiratory failure and none received non-invasive mechanical ventilation. Forty-five (94%) underwent intubation, 3 (6%) high flow nasal therapy (HFNT), 1 (2%) extracorporeal membrane oxygenation (ECMO) and 22 (46%) required prone position. After 15 days, 14/45 (31%) intubated patients died (13% within one week), 10/45 (22%) were extubated, and 21/45 (47%) underwent mechanical ventilation. Six patients had documented super-infection. Procalcitonin plasma above 0.5μg/L was associated with 16% vs. 19% (p=0.78) risk of death after 7 days.
Conclusion: This early experience with SARS-CoV-2 in Spain suggests that a strategy of right oxygenation avoiding non-invasive mechanical ventilation was life-saving. Seven-day mortality in SARS-CoV-2 requiring intubation was lower than 15%, with 80% of patients still requiring mechanical ventilation. After 15 days of ICU admission, half of patients remained intubated, whereas one third died.
Keywords: ARDS; COVID-19; Pneumonia; Procalcitonin.
Copyright © 2020 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.
Figures
References
- Jansson M., Liao X., Rello J., Strengthening I.C.U. health security for a coronavirus epidemic. Intensive Crit Care Nurs. 2020;57:102812. doi: 10.1016/j.iccn.2020.102812.
- Rello J., Tejada S., Userovici C., Arvaniti K., Pugin J., Waterer G. Coronavirus disease 2019 (COVID-19): a critical care perspective beyond China. Anaesth Crit Care Pain Med. 2020 doi: 10.1016/j.accpm.2020.03.001. Epub ahead of print.
- Cohen I.G., Crespo A.M., White D.B. Potential legal liability for withdrawing or withholding ventilators during COVID-19: assessing the risks and identifying needed reforms. JAMA. 2020 doi: 10.1001/jama.2020.5442. Epub ahead of print.
- Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K. Covid-19 in critically Ill patients in the Seattle Region - Case Series. N Engl J Med. 2020 doi: 10.1056/NEJMoa2004500. Epub ahead of print.
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
- Gattinoni L., Coppola S., Cressoni M., Busana M., Chiumello D. Covid-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome. AJRCCM. 2020 doi: 10.1164/rccm.202003-0817LE. [2020 Epub Ahead Print}
- World Health, Organisation Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance, V., 1.2. World Health Organ. 2020
- Rello J., Rodríguez A., Ibañez P., Socias L., Cebrian J., Marques A. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009;13:R148. doi: 10.1186/cc8044.
- Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutiérrez-Ocampo E., Villamizar-Peña R., Holguin-Rivera Y., Escalera-Antezana J.P. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 doi: 10.1016/j.tmaid.2020.101623. Epub ahead of print.
- Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05991-x. Epub ahead of print.
- Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. 2020 doi: 10.1016/S2213-2600(20)30079-5. Epub Ahead Print.
- Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–191. doi: 10.1016/j.cca.2020.03.004.
- Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F.X., Chong M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 doi: 10.1001/jama.2020.4326. Epub aHead of print.
- Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 doi: 10.1111/jth.14817. Epub Ahead of print.
- Iba T., Levy J.H., Warkentin T.E. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17:1989–1994. doi: 10.1111/jth.14578.
Source: PubMed